Please use this identifier to cite or link to this item:
Title: Recent thiazolidinediones as antidiabetics
Authors: Imran, Mohd
Ilyas, Babar
Khan, Suroor Ahmad
Keywords: Insulin sensitizing agents;Netoglitazone;Thiazolidinediones;Type 2 diabetes
Issue Date: Feb-2007
Publisher: CSIR
Abstract: Thiazolidinediones, a class of oral insulin sensitizing agents that improve insulin resistance, are agonists of peroxisome proliferator activated receptor-ϒ (PPAR-ϒ). Two clinically used drugs pioglitazone (ACTOS) and rosiglitazone (AVANDIA) have made a great contribution to therapy for type 2 diabetes. However, weight gain and hepatotoxicity are side effects of thiazolidinediones. For thiazolidinediones with lesser side effects, researchers are focusing on modification of side chain at C-5 of thiazolidinedione nucleus and its derivatization. Netoglitazone possesses both PPAR-⍺/ϒ dual agonistic activity. More thiazolidinedione derivatives like DRF-2189, PHT46, PMT13, DRF-2519 can be utilized as potent antidiabetic agents in future.
Page(s): 99-109
ISSN: 0022–4456
Appears in Collections:JSIR Vol.66(02) [February 2007]

Files in This Item:
File Description SizeFormat 
JSIR 66(2) (2007) 99-109.pdf314.25 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.